glp-1 optavia Lifestyle Program | & Lifemd GLP-1 LifeMD and Habits of

Last reviewed: June 9, 2026 Last updated: June 9, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations

Participants with obesity (body mass index (BMI) 30 kg/m) and moderate-to-severe KOA pain experienced significantly greater reductions in body weight and OA-related pain with weekly semaglutide injections compared to placebo [52]

For instance, a 2015 study found that Ozempic (semaglutide) did not affect the levels of oral birth control available in the bloodstream

The American Gut Project which had over 10k participants found that BMI and Akkermansia inversely correlated across the entire study population: 10% higher Akkermansia reduces risk for obesity approximately 26% on average

Increasing the dose of a GLP-1 can sometimes enhance weight loss or maintain consistent weight loss, explained Fatima Cody Stanford, MD, an obesity medicine scientist at Massachusetts General Hospital Digestive Healthcare Center in Boston